Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1961 3
1963 4
1964 5
1965 2
1966 6
1967 1
1968 8
1969 5
1970 10
1971 7
1972 9
1973 11
1974 4
1975 6
1976 3
1977 6
1978 11
1979 9
1980 8
1981 16
1982 10
1983 7
1984 8
1985 13
1986 12
1987 9
1988 9
1989 13
1990 10
1991 6
1992 9
1993 6
1994 6
1995 6
1996 6
1997 8
1998 5
1999 17
2000 8
2001 9
2002 8
2003 5
2004 10
2005 9
2006 13
2007 16
2008 18
2009 12
2010 15
2011 13
2012 20
2013 9
2014 14
2015 11
2016 11
2017 16
2018 6
2019 11
2020 5
2021 4
2022 9
2023 9
2024 10
2025 7
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

531 results

Results by year

Filters applied: . Clear all
Page 1
Mitotane (o,p'-DDD).
Gutierrez ML, Crooke ST. Gutierrez ML, et al. Cancer Treat Rev. 1980 Mar;7(1):49-55. doi: 10.1016/s0305-7372(80)80025-9. Cancer Treat Rev. 1980. PMID: 7397707 No abstract available.
[Metabolism of o,p'-DDD (mitotane) in human and animals. Actual notions and practical deductions (author's transl)].
Touitou Y, Bogdan A, Legrand JC, Desgrez P. Touitou Y, et al. Ann Endocrinol (Paris). 1977;38(1):13-25. Ann Endocrinol (Paris). 1977. PMID: 324349 Review. French.
The metabolism of o,p'-DDD (mitotane), a well-known inhibitor of adrenal steroidogenesis in man and animal, is reviewed. ...Serum specimens of treated patients were analyzed for o,p'-DDD during various phases of therapy: the levels and th …
The metabolism of o,p'-DDD (mitotane), a well-known inhibitor of adrenal steroidogenesis in man and animal, is reviewed …
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davis TE, Borden EC. Hogan TF, et al. Cancer. 1978 Nov;42(5):2177-81. doi: 10.1002/1097-0142(197811)42:5<2177::aid-cncr2820420514>3.0.co;2-x. Cancer. 1978. PMID: 719602
Four patients with adrenal cortical carcinoma were treated with standard doses of o,p'-DDD. Plasma levels of o,p'-DDD and its metabolites o,p'-DDA and o,p'-DDE were measured. o,p'-DDD was measurable for up to 8 months …
Four patients with adrenal cortical carcinoma were treated with standard doses of o,p'-DDD. Plasma levels of o, …
Cushing's syndrome.
Howlett TA, Rees LH, Besser GM. Howlett TA, et al. Clin Endocrinol Metab. 1985 Nov;14(4):911-45. doi: 10.1016/s0300-595x(85)80083-9. Clin Endocrinol Metab. 1985. PMID: 3002679 Review.
Cushing's disease is caused in the majority of cases by basophil pituitary microadenomas which may be successfully treated by trans-sphenoidal hypophysectomy. Treatment with metyrapone or o,p'-DDD can always induce a clinical remission but not a cure, and neu …
Cushing's disease is caused in the majority of cases by basophil pituitary microadenomas which may be successfully treated by trans-sphenoid …
Successful administration of mitotane (O, p'-DDD) in pediatric oncology.
Strobbe G, Fraipont F, Raimbault S, Mercier S, Stala T, Naveau M, Villain A, Sakji I, Defachelles AS, Feutry F, Marliot G. Strobbe G, et al. J Oncol Pharm Pract. 2022 Oct;28(7):1637-1640. doi: 10.1177/10781552221076795. Epub 2022 Jan 31. J Oncol Pharm Pract. 2022. PMID: 35098802
INTRODUCTION: Mitotane (o, p'-DDD) is a molecule that was developed many years ago for adrenal cortical carcinoma, but no suitable pediatric dosage form is available for administration to young children. ...
INTRODUCTION: Mitotane (o, p'-DDD) is a molecule that was developed many years ago for adrenal cortical carcinoma, but …
The organochlorine o,p'-DDD disrupts the adrenal steroidogenic signaling pathway in rainbow trout (Oncorhynchus mykiss).
Lacroix M, Hontela A. Lacroix M, et al. Toxicol Appl Pharmacol. 2003 Aug 1;190(3):197-205. doi: 10.1016/s0041-008x(03)00168-6. Toxicol Appl Pharmacol. 2003. PMID: 12902190
Acute exposures to o,p'-DDD inhibited ACTH-stimulated cortisol secretion while cell viability decreased significantly only at the highest concentration tested (200 microM o,p'-DDD). ...In contrast, basal cortisol secretion was stimulated …
Acute exposures to o,p'-DDD inhibited ACTH-stimulated cortisol secretion while cell viability decreased significantly o …
Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia.
Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR, Besser GM. Maher VM, et al. Q J Med. 1992 Sep;84(305):671-9. Q J Med. 1992. PMID: 1480741
This paper examined the mechanism of that effect in 30 patients with Cushing's syndrome treated with o,p'DDD during the past 10 years. o,p'DDD increased serum cholesterol by 68 per cent, mainly by increasing LDL-cholesterol. ...Increases …
This paper examined the mechanism of that effect in 30 patients with Cushing's syndrome treated with o,p'DDD during the …
Interindividual differences in o,p'-DDD enantiomer kinetics examined in Gottingen minipigs.
Cantillana T, Lindström V, Eriksson L, Brandt I, Bergman A. Cantillana T, et al. Chemosphere. 2009 Jun;76(2):167-72. doi: 10.1016/j.chemosphere.2009.03.050. Epub 2009 Apr 25. Chemosphere. 2009. PMID: 19394667
The mean concentrations in liver and kidney were 500+/-300 pg g(-1)f.w. and 90+/-50 pg g(-1)f.w., respectively. The enantiomers of o,p'-DDD were isolated by HPLC and the absolute configuration of the enantiomers were determined by X-ray crystallography and po …
The mean concentrations in liver and kidney were 500+/-300 pg g(-1)f.w. and 90+/-50 pg g(-1)f.w., respectively. The enantiomers of o, …
The distribution of o,p'-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia.
Gebhardt DO, Moolenaar AJ, van Seters AP, van der Velde EA, Gevers Leuven JA. Gebhardt DO, et al. Cancer Chemother Pharmacol. 1992;29(4):331-4. doi: 10.1007/BF00685956. Cancer Chemother Pharmacol. 1992. PMID: 1537084
We found that the distribution of the lipophilic chemotherapeutic agent o,p'-DDD (mitotane) among serum (lipo)proteins was altered in hypertriglyceridemia, with relatively more o,p'-DDD accumulating in the chylomicron and very-low-density …
We found that the distribution of the lipophilic chemotherapeutic agent o,p'-DDD (mitotane) among serum (lipo)proteins …
o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.
Touitou Y, Moolenaar AJ, Bogdan A, Auzéby A, Luton JP. Touitou Y, et al. Eur J Clin Pharmacol. 1985;29(4):483-7. doi: 10.1007/BF00613466. Eur J Clin Pharmacol. 1985. PMID: 4092727
o,p'-DDD is an inhibitor of adrenal steroid synthesis currently used for therapy of Cushing's syndrome. Conflicting data have been published on the relationship between the plasma level of the drug and its clinical and biological effects. The levels of o …
o,p'-DDD is an inhibitor of adrenal steroid synthesis currently used for therapy of Cushing's syndrome. Conflicting dat …
531 results